Why the study?
Sacubitril/valsartan improves outcomes in heart failure with reduced ejection fraction, but its impact on right heart failure remains unknown.
Does sacubitril/valsartan improve symptoms and right heart function in patients with right heart failure?
Does sacubitril/valsartan improve symptoms and right heart function in patients with right heart failure?
This case report suggests sacubitril/valsartan may be beneficial for right heart failure, highlighting the need for larger studies.
May suggest benefit in right heart failure; leaves open confirmation in randomized trials.
Sacubitril/valsartan improves mortality and morbidity in patients with heart failure with reduced ejection fraction. However, its impact on right heart failure remains unknown. We experienced a 70-year-old man who was started on sacubitril/valsartan to treat his right heart failure with moderate tricuspid regurgitation. Following the 3-month sacubitril/valsartan treatment, a functional and geological improvement was observed in the right heart as well as amelioration of his congestive symptoms. Sacubitril/valsartan might improve right heart failure in addition to conventionally-proven left heart failure. Further large-scale studies are warranted to validate our findings.
No takes yet. Share an insight, caveat, or question.
Imamura et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: